Quick Summary
Ultrorelix 0.25mg Injection
Last updated on 21 Jul 2026 | 05:28 AM (IST)
₹657
MRP: ₹1312.5
(You Save ₹655.5)
1 VIAL(s)
Ultrorelix 0.25mg Injection
Salt Composition
CETRORELIXMarketer
ERMINNE PHARMACEUTICALS
Prepaid Only. Non-Returnable.
50% OFF
₹657
MRP: ₹1,312.50
Inclusive of all taxes
50% Off
Salt Composition
CETRORELIXMarketer
ERMINNE PHARMACEUTICALS
Prepaid Only. Non-Returnable.
Dispatch: Today
Order In: 0h 0m 0s
0h 0m 0s
Order before timer ends to ensure your medicine is dispatched at...
Substitutes
Cetrocare 0.25mg Injection
GUFIC BIOSCIENC...
₹ 855.00/injection
31% costlier
Gonapress 0.25mg Injection
FERRING PHARMAC...
₹ 908.00/injection
39% costlier
Ovucet 0.25mg Injection
ZYDUS CADILA
₹ 954.00/injection
46% costlier
Sanrox 0.25mg Injection
SANZYME PVT LTD
₹ 960.00/injection
47% costlier
Introduction to Ultrorelix 0.25mg Injection
Ultrorelix 0.25mg Injection are the hormonal agents in the category of gonadotropin-releasing hormone antagonists containing the active ingredient Cetrorelix. It is used to treat female infertility (the inability of a woman to conceive a child or carry a pregnancy to full term). This drug helps to synchronise the development of multiple follicles and ensures that they can be retrieved during the IVF procedure.
This drug is contraindicated in individuals with known hypersensitivity or allergy to it or its component. Inform your physician if you have kidney problems and liver problems. Special monitoring or dose adjustments are required in these situations. Ultrorelix 0.25mg Injection is often used with other medications to stimulate the ovaries as part of fertility treatment. It can mainly increase the chance of developing Ovarian Hyperstimulation Syndrome (OHSS), a condition in which the ovaries become enlarged, and cysts may form. Contact your physician if you experience severe pelvic pain, bloating, nausea, vomiting, or sudden weight gain, as these symptoms may indicate OHSS. Report to your physician immediately if you experience sudden life-threatening allergic reactions such as difficulty breathing or wheezing, swelling, rash, itching, fever, and chills.
This drug is not intended for use in children. Please inform your physician about any other medications you use, have recently used, or may use, as they can interact with Cetrorelix. The use of this drug in pregnant and breastfeeding women is not recommended. Consult your doctor for more advice before initiating the treatment.
Uses of Ultrorelix 0.25mg Injection
- Female infertility
Therapeutic Effects of Ultrorelix 0.25mg Injection
Cetrorelix works by blocking the effects of GnRH, a hormone that triggers the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). By inhibiting GnRH, this drug helps regulate ovulation timing during ART procedures.
Interaction of Ultrorelix 0.25mg Injection with other drugs
Inform your doctor about all your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications interact with Ultrorelix 0.25mg Injection and reduce their effectiveness by causing undesirable side effects.
More Information about Ultrorelix 0.25mg Injection
- Store Ultrorelix 0.25mg Injection in a refrigerator at (2 °C to 8°C).
- Do not freeze.
- Keep Ultrorelix 0.25mg Injection out of sight and reach of children.
How to consume Ultrorelix 0.25mg Injection
Ultrorelix 0.25mg Injection will be given to you by a doctor or other healthcare professional. They will administer the injection in the fatty tissues just under the skin of your belly (subcutaneously). To minimise skin irritation, your physician will select a different area of your belly for each injection.
Safety Advice for Ultrorelix 0.25mg Injection
Breast Feeding
The use of Ultrorelix 0.25mg Injection is not recommended during breastfeeding. Inform your physician if you are breastfeeding.
Alcohol
It is unknown whether consuming alcohol while administering Ultrorelix 0.25mg Injection is safe. Please speak with your physician.
Liver
Ultrorelix 0.25mg Injection should be administered cautiously in patients with liver failure. Dose adjustments are necessary if you have liver problems. Inform your physician if you have any liver disease before initiating the therapy.
Lungs
It is unknown whether Ultrorelix 0.25mg Injection can be used in patients with lung problems. Consult your physician if you have any lung diseases before starting the treatment.
Driving
Driving vehicles or operating heavy machinery is safe after administering Ultrorelix 0.25mg Injection. It doesn't affect your ability to drive and use machines.
Pregnancy
Ultrorelix 0.25mg Injection may be unsafe to use during pregnancy. Inform your physician if you are pregnant, suspecting, or planning to get pregnant during the treatment.
Side Effects of Ultrorelix 0.25mg Injection
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Serious
- Injection site reactions ( pain, itching)
- Ovarian hyperstimulation syndrome (OHSS)
- Swelling of face, lips, tongue, or throat
Common
- Headache
- Nausea
- Abdominal discomfort
- Fatigue
Word of Advice
The process of fertility treatment can be emotionally challenging. Look for support from your partner, family, and friends groups to help you navigate any emotional ups and downs during the treatment. It is important to maintain a healthy lifestyle during fertility treatment. It includes eating a balanced diet, engaging in regular physical activity (unless advised by your healthcare provider), managing stress levels, avoiding smoking, and excessive alcohol consumption. Store the Ultrorelix 0.25mg Injection medication as per the manufacturer's instructions. Please keep it in a cool, dry place and protect it from light.
FAQs about Ultrorelix 0.25mg Injection
Q1.
Is Ultrorelix 0.25mg Injection available over the counter?
No, Ultrorelix 0.25mg Injection is not available over the counter. It is a prescription medication that must be obtained from a healthcare provider.
Q2.
How is Ultrorelix 0.25mg Injection administered?
Ultrorelix 0.25mg Injection is administered as a subcutaneous injection only, meaning it is injected just beneath the skin.
Q3.
What is the required duration for Ultrorelix 0.25mg Injection treatment?
The duration of Ultrorelix 0.25mg Injection treatment can vary depending on the individual and the ART protocol. It is usually initiated a few days before the expected time of ovulation and continues for several days.
Q4.
Can Ultrorelix 0.25mg Injection be used during pregnancy?
No, Ultrorelix 0.25mg Injection is not intended for use during pregnancy. It prevents premature ovulation and is typically discontinued once pregnancy is achieved.
Q5.
How does Ultrorelix 0.25mg Injection work in IVF?
Ultrorelix 0.25mg Injection is primarily used in ART procedures, such as in vitro fertilization (IVF), to prevent premature ovulation. It helps to synchronize the timing of egg retrieval and improve the success rates of these procedures.
Q6.
Can Ultrorelix 0.25mg Injection cause weight gain?
Weight gain is not usually reported as a side effect of Ultrorelix 0.25mg Injection. If you notice any significant changes in your weight during treatment, it is best to consult your physician to determine the cause.
Fact Box of Ultrorelix 0.25mg Injection
Molecule Name: Cetrorelix | Therapeutic Class: Hormonal agents |
Pharmacological Class: Gonadotropin-releasing hormone antagonists | Indications: Female infertility |
References
- Merck Europe BV, Electronic medicines compendium (EMC), [Revised on Jan 2021] [ Accessed on 12th June 2023], https://www.medicines.org.uk/emc/files/pil.1605.pdf
- EMD Serono, Inc, US Food and Drug Administration, [Revised on April 2008] [Accessed on 12th June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021197s010lbl.pdf
- Dominique Finas et al.; Cetrorelix in the treatment of female infertility and endometriosis; Expert Opinion on Pharmacotherapy; Published on Oct 2006; Accessed on 12th June 2023; https://pubmed.ncbi.nlm.nih.gov/17020439/
- KD Tripathi, Essentials of Medical Pharmacology, Anterior pituitary hormones, 7th edition, 2013, 243.
- Bertram.G.Katzung, Basic and Clinical Pharmacology, Endocrine drugs, 14th edition, 2017, 678.
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. Vijayalakshmi N.
BDS
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 21 Jul 2026 | 05:28 AM (IST)
Want to know more?
Read Our Editorial Policy